Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	49.8	31.08	1.2	0.14	0.3
Revenue Growth (YoY)	60.24%	2481.48%	766.19%	-53.36%	-98.76%
Cost of Revenue	0.27	0.62	0.09	-	-
Gross Profit	49.53	30.47	1.12	0.14	0.3
Selling, General & Admin	37.32	143.1	113.98	48.08	32.34
Research & Development	61.12	84.48	58.89	52.82	55.05
Total Operating Expenses	98.44	227.58	172.87	100.9	87.39
Operating Income	-48.91	-197.12	-171.75	-100.76	-87.09
Other Non-Operating Income (Expense)	-1.43	-3.29	-5.37	-1.18	-0.67
Total Non-Operating Income (Expense)	-1.43	-3.29	-5.37	-1.18	-0.67
Pretax Income	-50.34	-200.4	-177.12	-101.94	-87.76
Net Income	-50.34	-200.4	-177.12	-101.94	-87.76
Net Income to Common	-50.34	-200.4	-177.12	-101.94	-87.76
Shares Outstanding (Basic)	363	320	221	166	146
Shares Outstanding (Diluted)	363	320	221	166	146
Shares Change (YoY)	13.44%	44.73%	33.42%	13.79%	31.41%
EPS (Basic)	-0.14	-0.63	-0.80	-0.62	-0.60
EPS (Diluted)	-0.14	-0.63	-0.80	-0.62	-0.60
Shares Outstanding	363.47	361.49	244.93	188.73	148.92
Free Cash Flow	-67.85	-179.81	-162.37	-90.18	-88.24
Free Cash Flow Per Share	-0.19	-0.56	-0.73	-0.54	-0.61
Gross Margin	99.45%	98.02%	92.94%	100.00%	100.00%
Operating Margin	-98.21%	-634.20%	-14265.00%	-72489.20%	-29224.80%
Profit Margin	-101.08%	-644.78%	-14710.90%	-73341.00%	-29449.00%
FCF Margin	-136.24%	-578.52%	-13485.60%	-64875.50%	-29610.10%
EBITDA	-48.29	-196.58	-171.2	-100.33	-86.8
EBITDA Margin	-96.96%	-632.49%	-14218.90%	-72182.00%	-29126.80%
EBIT	-48.91	-197.12	-171.75	-100.76	-87.09
EBIT Margin	-98.21%	-634.20%	-14265.00%	-72489.20%	-29224.80%

Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q